Integrated Due Diligence for Keensight Capital | 3P Biopharmaceuticals

Larka is pleased to announce that it performed the Commercial Due-Diligence, Operational Due-Diligence and Technical Due-Diligence for Keensight Capital, the new majority shareholder of 3P Biopharmaceuticals.



Larka's Mergers & Acquisitions team advised Keensight Capital on all relevant strategic, commercial and operational aspects of the transaction. In addition, Larka also performed the Quality & Regulatory Due Diligence of the contract service provider. 

Keensight Capital, one of the leading private equity managers dedicated to pan-European Growth Buyout investments, acquired Infarco’s majority stake in 3P Biopharmaceuticals, a leading Contract Development and Manufacturing Organization – CDMO – specialized in the process development and GMP manufacturing of biologics for both microbial and mammalian expression systems.


“We are proud to be the new shareholders of 3P Biopharmeceuticals, one of the European leaders in the biologics CDMO space. We have been happy to work with Larka on this investment opportunity. Pierre-Anthony Brioir and his team confirmed once again the level of excellence and expertise they have in this field.”

Javier Lopez Moras, Director at Keensight Capital


Founded in 2006 and based near Pamplona, Spain, 3P Biopharmaceuticals employs 240 people and offers a complete biologics production service, from preclinical and clinical stages, all the way to full-scale commercial manufacturing.

Larka performed an Integrated Due Diligence to support Keensight Capital during the acquisition of 3P Biopharmaceuticals.


“After our successful collaboration last year on another transaction in this field, we are very proud to have worked again with Keensight on this new successful deal. 3P Biopharmaceuticals has a strong growth potential, with a wide range of services covering the whole value chain, from preclinical work to commercial supply. Combined with the highly skilled and experienced team of Keensight, 3P Biopharmaceuticals should become a major CDMO player in Europe in the coming years.”

Pierre-Anthony Brioir, Director at Larka


About Larka

Larka is a management consulting firm, exclusively dedicated to the Biotech and Pharma industry. We assist small Biotech or large Pharma companies, Contract Services Providers or Equipment Suppliers, Venture Capital or Private Equity firms, in their development or in managing complex situations. Active in Technical, Organizational, Commercial and Strategic operations, Larka has developed a unique combination of expertise which covers CMC & Outsourcing activities, Operational & Commercial excellence, Marketing & Sales, Corporate Strategy and M&A.

For more information, please visit


About Keensight Capital

Keensight Capital, one of the leading European Growth Buyout firms, is committed to supporting entrepreneurs as they implement their growth strategies. For 20 years, Keensight Capital’s team of seasoned professionals has leveraged their knowledge of investment and growth industries to invest for the long term in profitable companies with high growth potential and revenues in the range of €15 million to €250 million. Drawing on its expertise in the Information Technology/Internet and Healthcare/Wellbeing sectors, Keensight identifies the best investment opportunities in Europe and works closely with management teams to develop and achieve their strategic vision.

For more information, please visit